Matrix Remodeling Enzymes As Potential Fluid Biomarkers of Neurodegeneration in Alzheimer's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 19

PMID 38891891

Authors

Jelena Basic

Vuk Milosevic

Branka Djordjevic

Vladana Stojiljkovic

Milica Zivanovic

Nikola Stefanovic

Aleksandra Aracki Trenkic

Dragan Stojanov

Tatjana Jevtovic Stoimenov

Ivana Stojanovic

Affiliations

Soon will be listed here.

Abstract

This study investigated the diagnostic accuracy of plasma biomarkers-specifically, matrix metalloproteinase (MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), CD147, and the MMP-/TIMP-1 ratio in patients with Alzheimer's disease (AD) dementia. The research cohort comprised patients diagnosed with probable AD dementia and a control group of cognitively unimpaired (CU) individuals. Neuroradiological assessments included brain magnetic resonance imaging (MRI) following dementia protocols, with subsequent volumetric analysis. Additionally, cerebrospinal fluid (CSF) AD biomarkers were classified using the A/T/N system, and apolipoprotein E () ε4 carrier status was determined. Findings revealed elevated plasma levels of MMP-9 and TIMP-1 in AD dementia patients compared to CU individuals. Receiver operating characteristic (ROC) curve analysis demonstrated significant differences in the areas under the curve (AUC) for MMP-9 ( < 0.001) and TIMP-1 ( < 0.001). Notably, plasma TIMP-1 levels were significantly lower in ε4+ patients than in ε4- patients ( = 0.041). Furthermore, ε4+ patients exhibited reduced hippocampal volume, particularly in total, right, and left hippocampal measurements. TIMP-1 levels exhibited a positive correlation, while the MMP-9/TIMP-1 ratio showed a negative correlation with hippocampal volume parameters. This study sheds light on the potential use of TIMP-1 as a diagnostic marker and its association with hippocampal changes in AD.

References

Liu J, Li X, Qu J . Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer's disease. Neuroreport. 2023; 34(15):767-772. DOI: 10.1097/WNR.0000000000001952. View

Jack Jr C, Albert M, Knopman D, McKhann G, Sperling R, Carrillo M . Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):257-62. PMC: 3096735. DOI: 10.1016/j.jalz.2011.03.004. View

Abe K, Chiba Y, Ide K, Yoshimi A, Asami T, Suda A . Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database. J Prev Alzheimers Dis. 2022; 9(2):331-337. DOI: 10.14283/jpad.2022.19. View

Bachmeier C, Shackleton B, Ojo J, Paris D, Mullan M, Crawford F . Apolipoprotein E isoform-specific effects on lipoprotein receptor processing. Neuromolecular Med. 2014; 16(4):686-96. PMC: 4280344. DOI: 10.1007/s12017-014-8318-6. View

Cabral-Pacheco G, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuna J, Perez-Romero B, Guerrero-Rodriguez J . The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci. 2021; 21(24). PMC: 7767220. DOI: 10.3390/ijms21249739. View

Bruno M, Mufson E, Wuu J, Cuello A . Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol. 2009; 68(12):1309-18. PMC: 2810197. DOI: 10.1097/NEN.0b013e3181c22569. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

ODwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J . Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One. 2012; 7(11):e48895. PMC: 3494711. DOI: 10.1371/journal.pone.0048895. View

Shackleton B, Ringland C, Abdullah L, Mullan M, Crawford F, Bachmeier C . Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier. Mol Neurobiol. 2019; 56(12):8296-8305. PMC: 6842100. DOI: 10.1007/s12035-019-01672-z. View

10.

Du J, Li S, Su Y, Wang H, Liu H, Cui H . The role of extracellular matrix metalloproteinase inducer on the action of dihydrotestosterone against the cellular damage induced by Aβ. Mol Cell Endocrinol. 2019; 498:110536. DOI: 10.1016/j.mce.2019.110536. View

11.

Behl T, Kaur G, Sehgal A, Bhardwaj S, Singh S, Buhas C . Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. Int J Mol Sci. 2021; 22(3). PMC: 7866808. DOI: 10.3390/ijms22031413. View

12.

. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 18(1):88-106. PMC: 6291454. DOI: 10.1016/S1474-4422(18)30403-4. View

13.

Troutwine B, Hamid L, Lysaker C, Strope T, Wilkins H . Apolipoprotein E and Alzheimer's disease. Acta Pharm Sin B. 2022; 12(2):496-510. PMC: 8897057. DOI: 10.1016/j.apsb.2021.10.002. View

14.

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

15.

Horstmann S, Budig L, Gardner H, Koziol J, Deuschle M, Schilling C . Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr. 2010; 22(6):966-72. DOI: 10.1017/S1041610210000827. View

16.

Milosevic V, Malobabic M, Stojanovic I, Basic J . Importance of a functional measure in the evaluation of patients in a memory clinic: Validation of the Serbian version of the Amsterdam instrumental activities of daily living questionnaire. Clin Neurol Neurosurg. 2022; 214:107165. DOI: 10.1016/j.clineuro.2022.107165. View

17.

Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias G, Maccioni R . Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014; 8:112. PMC: 4001039. DOI: 10.3389/fncel.2014.00112. View

18.

Iannucci J, Sen A, Grammas P . Isoform-Specific Effects of Apolipoprotein E on Markers of Inflammation and Toxicity in Brain Glia and Neuronal Cells In Vitro. Curr Issues Mol Biol. 2021; 43(1):215-225. PMC: 8928993. DOI: 10.3390/cimb43010018. View

19.

Park H, Suh C, Heo H, Shim W, Kim S . Diagnostic performance of hippocampal volumetry in Alzheimer's disease or mild cognitive impairment: a meta-analysis. Eur Radiol. 2022; 32(10):6979-6991. DOI: 10.1007/s00330-022-08838-9. View

20.

Stomrud E, Bjorkqvist M, Janciauskiene S, Minthon L, Hansson O . Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res Ther. 2010; 2(3):20. PMC: 2919700. DOI: 10.1186/alzrt44. View